
Boston Scientific shares plunge 53% amid lowered growth forecasts and product challenges
Boston Scientific's stock has fallen about 53% over the past year due to lowered full-year 2026 growth guidance, slowing WATCHMAN device sales, loss of electrophysiology market share, and mixed clinical trial results from CHAMPION-AF. The company now...
